Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Diabeloop for Highly Unstable Type 1 Diabetes (DBLHU)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04042207
Recruitment Status : Active, not recruiting
First Posted : August 1, 2019
Last Update Posted : October 8, 2020
Sponsor:
Information provided by (Responsible Party):
Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète

Brief Summary:

Feasibility study, comparing experimental treatment (DBLHU closed-loop system) with reference treatment (Low Glucose Predictive Suspend system) in 7 patients going through a series of N-of-1 trials. Each N-of-1 trial consists in a prospectively planned, multiple crossover study in a single individual. Two blocks of two periods of four weeks each (closed loop or open loop) will be conducted. Within each block, the sequence closed loop-open loop or open loop-close loop is randomized. Outcomes will be analyzed on the third and fourth weeks of period.

A remote monitoring system managed by specialized nurse on behalf of diabetologist, is provided in closed-loop session.

An extension period of 48 weeks with the DBLHU System (closed-loop condition) will be performed at the end of the crossover study phase in real life conditions (without remote monitoring).


Condition or disease Intervention/treatment Phase
Diabetes Mellitus, Type 1 Diabetes Mellitus, Brittle Closed-Loop Device: Low Glucose Predictive Suspend system Device: DBLHU System Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 7 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: N-of-1 trials consists in a prospectively planned, multiple crossover study in a single individual.
Masking: None (Open Label)
Primary Purpose: Device Feasibility
Official Title: In Adults With Very Unstable Type 1 Diabetes, is the DBLHU Closed-Loop Insulin Delivery System Able to Improve Blood Glycemic Control Compared to Low-Glucose-Predictive-Suspend System: Two-center, Randomized, Open-label Study
Actual Study Start Date : September 3, 2019
Actual Primary Completion Date : February 27, 2020
Estimated Study Completion Date : March 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1

Arm Intervention/treatment
Active Comparator: Reference treatment (Open-Loop)
Sensor-augmented pump therapy (SAP) namely the Low Glucose Predictive Suspend system or LGPS and a blinded glucose sensor (Dexcom G6) followed by a 48-week extension period in closed-loop condition
Device: Low Glucose Predictive Suspend system
consists of sensor-augmented pump therapy (SAP) / Low Glucose Predictive Suspend system (with predictive low glucose management technology)
Other Name: Open-loop condition

Device: DBLHU System
DBLHU system embeds a regulation algorithm to automatically regulate the patient's glycaemia. It takes as input glycaemia value received every 5 minutes from the CGM and patient inputs related to meals and physical activities and it calculates the amount of insulin to be delivered. It sends this information to the pump that automatically delivers this quantity.
Other Name: Closed-loop condition

Experimental: DBLHU system (Closed-Loop)
DBLHU software (a Model Predictive Control [MPC]-based glucose control algorithm) running on handset associated with the six-generation glucose sensor (Dexcom G6) and Kaleido insulin pump followed by a 48-week extension period in closed-loop condition
Device: DBLHU System
DBLHU system embeds a regulation algorithm to automatically regulate the patient's glycaemia. It takes as input glycaemia value received every 5 minutes from the CGM and patient inputs related to meals and physical activities and it calculates the amount of insulin to be delivered. It sends this information to the pump that automatically delivers this quantity.
Other Name: Closed-loop condition




Primary Outcome Measures :
  1. Percentage of CGM time in glucose range 70-180 mg/dl, during 24 hours periods for the third and fourth week for each treatment period [ Time Frame: 14 days for each treatment period ]
    Measured by continuous glucose monitoring


Secondary Outcome Measures :
  1. Evolution over time of the DBLHU system's performance on a day-to-day and determination of the optimization delay of glycemic control [ Time Frame: Over twenty-four hour periods on the four weeks of each treatment period and of the 24-week and 48-week extented CL period. ]
    Measured by continuous glucose monitoring

  2. Percent of CGM time in glucose range 70-180 mg/dl during nighttime. [ Time Frame: Overnight (defined as 00:00 to 06:00) periods on the third and fourth week of each treatment period and during the last 4 weeks of the 24-week and 48-week extented CL period. ]
    Measured by continuous glucose monitoring

  3. Percent of CGM time in glucose range 70-180 mg/dl during daytime. [ Time Frame: Over daytime (defined as 06:00 to 00:00) periods on the third and fourth week of each treatment period and during the last 4 weeks of the 24-week and 48-week extented CL period. ]
    Measured by continuous glucose monitoring

  4. Percent of CGM time with glucose < 70mg/dl, < 60mg/dl, < 54mg/dl and < 50mg/dl [ Time Frame: Over twenty-four hour periods on the third and fourth weeks of each treatment period and during the last 4 weeks of the 24-week and 48-week extented CL period. ]
    Measured by continuous glucose monitoring

  5. Percent of CGM time with glucose > 180mg/dl, > 250mg/dl, > 300mg/dl and > 360mg/dl [ Time Frame: Over twenty-four hour periods on the third and fourth weeks of each treatment period and during the last 4 weeks of the 24-week and 48-week extented CL period. ]
    Measured by continuous glucose monitoring

  6. Average glycemia level [ Time Frame: Over twenty-four hour periods on the third and fourth weeks of each treatment period and during the last 4 weeks of the 24-week and 48-week extented CL period. ]
    Measured by continuous glucose monitoring

  7. Estimated HbA1c (eHbA1c) levels / glucose management indicator (GMI) [ Time Frame: Over twenty-four hour periods on the third and fourth weeks of each treatment period and during the last 4 weeks of the 24-week and 48-week extented CL period. ]
    Measured by continuous glucose monitoring

  8. HbA1c levels [ Time Frame: HbA1c value at the week 24 and week 48 of extented CL period. ]
    Measured by blood sampling

  9. Glucose coefficient of variation (CV) and Standard deviation (SD) [ Time Frame: Over twenty-four hour periods on the third and fourth weeks of each treatment period and during the last 4 weeks of the 24-week and 48-week extented CL period. ]
    Measured by continuous glucose monitoring

  10. Rate of CGM excursions below 54 mg/dl (3.0 mM) for at least 15 min [ Time Frame: Over twenty-four hour periods on the third and fourth weeks of each treatment period and during the last 4 weeks of the 24-week and 48-week extented CL period. ]
    Mean time spent in hypoglycaemia, defined as sensor glucose values of 54 mg/dL (3∙0 mmol/L) or lower for more than 15 min consecutively

  11. Comparison of MAGE index and Low Blood Glucose Index (LBGI) [ Time Frame: Over twenty-four hour periods on the third and fourth weeks of each treatment period and during 24-week extension period ]
    Mean amplitude of glucose excursions and Low Glucose index as measured by continuous glucose monitoring

  12. Number of acute metabolic events (severe hypoglycemia, severe Diabetic Ketoacidosis [DKA]) [ Time Frame: During 4 weeks of each treatment period and during 24-week and 48-week extension period ]

    Measured by continuous glucose monitoring. Number of severe hypoglycemia is defined as any event requiring third party assistance.

    DKA events. Subjects will be asked to measure blood ketone levels on if their interstitial glucose is above 300 mg/l beyond the usual timeframe following a meal, as part of the safety evaluation for hyperglycemia.


  13. Number of severe hypoglycemia with loss of consciousness [ Time Frame: During 4 weeks of each treatment period and during 24-week and 48-week extension period ]
    Number of severe hypoglycemia with loss of consciousness

  14. Number of hospitalizations for severe hypoglycemia or ketoacidosis [ Time Frame: During 4 weeks of each treatment period and during 24-week and 48-week extension period ]
    Number of hospitalizations

  15. For the use and the acceptance, a satisfaction survey will be done on the daily management of diabetes, the modification of daily life with the system dan the fear of hypoglycemia [ Time Frame: after baseline period (2-week); after crossover period; after 24-week and after 48-week extension period ]
    DTSQ satisfaction questionnaire, with scale from 6 to 0 where 0 is the worth and 6 the best outcome.

  16. Percentage of CGM time in glucose range 70-180 mg/dl, during 24 hours periods [ Time Frame: 24-week and 48-week extension period ]
    Measured by continuous glucose monitoring



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   22 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject (aged 22 or more) with Type 1 diabetes for at least 5 years and confirmed C peptide negative
  • Treated with continuous subcutaneous insulin infusion (CSII) for ≥ 6 months,
  • Trained to carbohydrate counting/flexible insulin therapy,
  • Subject that had experienced, despite optimal diabetes management and prior to any equipment with Smartguard technology, glucose instability as defined by at least 2 of the following criteria which would have led to eligibility for pancreatic islet transplantation:

    • occurrence of at least 1 severe hypoglycemic episode during the past 12 months (need for third party),
    • occurrence of ketoacidosis (hospitalization in ICU) without explanation
    • Impaired awareness of hypoglycemia (Clark Score ≥ 4; Gold Score > 4)
    • glucose levels: standard deviation > 50% of the arithmetic mean value on glucose meter or > 40 mg/dl on CGM on a 14-day recording
    • glucose levels: MAGE (mean amplitude of glucose excursions) index > 60 mg/dl
    • glucose levels: coefficient of variation (CV) > 36%
  • with persisting extreme glucose variability despite optimal medical care
  • with contra-indication or no agreement to undertake pancreatic islet transplantation or pancreas transplantation.
  • Subject willing to wear the DBLHU system continuously throughout the study

Exclusion Criteria:

  • patient with type 2 diabetes
  • age < 22 years old
  • patient without any social or familial support able to intervene in case of severe hypoglycemic event
  • any permanent and severe condition able to interact with the normal course of the study
  • patient with insulin-resistance defined by insulin requirements > 1.5U/kg/d
  • patient with a daily dose of insulin required greater than 90 units
  • patient receiving a total daily dose of insulin less than 8 U
  • use of any insulin that is not 100 U/mL fast-acting insulin analog
  • patient suffering from a serious illness or a treatment that might significantly impair diabetes physiology, i.e. glucose-insulin interactions, that might interfere with the medical device (for example irregular treatment of steroids)
  • patient having severe problems of uncorrected hearing and/or visual acuity
  • patient who is unable to understand and perform all the instructions provided by Diabeloop SA
  • patient not willing to perform ≥4 finger stick blood glucose measurements daily
  • patients that have frequent exposure to magnetic resonance imaging (MRI), computed tomography (CT) scan, or high-frequency electrical heat (diathermy) treatment.
  • patient who has had a pancreatectomy or who has pancreatic malfunctions
  • patient having severely altered renal function (Creatinine clearance < 30ml/min)
  • patient on dialysis
  • pregnancy or breast-feeding patient, or project of pregnancy during the next 6 months
  • lack of effective contraception in women of childbearing potential
  • all conditions excluding participation to clinical research as defined in France

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04042207


Locations
Layout table for location information
France
Grenoble Alpes University Hospital
Grenoble, France, 38700
Lille University Hospital
Lille, France, 59037
Sponsors and Collaborators
Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète
Investigators
Layout table for investigator information
Principal Investigator: Pierre Yves BENHAMOU, Pr University Hospital, Grenoble
Layout table for additonal information
Responsible Party: Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète
ClinicalTrials.gov Identifier: NCT04042207    
Other Study ID Numbers: 2019-A01365-52
First Posted: August 1, 2019    Key Record Dates
Last Update Posted: October 8, 2020
Last Verified: October 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète:
Artificial pancreas
Very Unstable Type 1 diabetes
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases